Direct compression of Dahuang Huangqin Powder Veterinary Grade API on a rotary press fitted with 9 mm B-tooling is generally abandoned after pilot runs because the spray-dried extract exhibits cohesive hopper flow and laminates at compression pressure above 12 kN when residual moisture exceeds 4.5% w/w. A wet-granulated intermediate is produced in a top-spray fluidized bed with 2.5–5.0% w/w povidone K30 binder dissolved in 70% v/v ethanol-water, and the granulate is milled through a 0.8 mm screen. The starting tablet formulation is 500 mg total mass containing 150 mg API, microcrystalline cellulose 102 q.s., crospovidone 4% w/w, sodium starch glycolate 2% w/w, and silicon dioxide 0.5% w/w. Magnesium stearate is limited to 0.8% w/w and blended for no more than 3 min in a V-blender to avoid lower punch filming. The finished tablets are compressed to hardness 50–80 N, with friability below 0.8% according to USP <1216>, disintegration under 15 min in 0.1 N hydrochloric acid according to USP <701>, and a provisional dissolution acceptance of not less than 70% baicalin release at 45 min using USP <711> apparatus 2 at 50 rpm. Terminal finished product is an uncoated oral tablet for weaned piglets and poultry; moisture-barrier PVC/PVdC-aluminium blister packaging is required because the extract softens and darkens when equilibrated at relative humidity above 60%.

If a dry-granulation route is required because the API is sensitive to aqueous binder fluid, a roller compactor with roll pressure 4–6 MPa is substituted, followed by milling through a 0.8 mm screen. The same tablet formula can then be compressed, but disintegration may extend toward 20 min unless crospovidone is increased to 6% w/w. Film coating with hydroxypropyl methylcellulose is not recommended above 3% weight gain because it slows marker release in gastric fluid and increases the risk of core softening in high-humidity storage. Stability protocols follow VICH GL3 with storage at 40 °C/75% RH and 25 °C/60% RH; published data for longer storage of this specific formulation configuration is limited.

Why Does Sterilizing-Grade Filtration of Reconstituted Dahuang Huangqin Powder Fail Below pH 5.5?

Baicalin and the anthraquinone aglycones derived from Dahuang and Huangqin show pH-dependent aqueous solubility; below pH 5.5 the extracts form visible colloidal aggregates that blind 0.22 µm polyethersulfone filter capsules within the first 5–10 min of filtration at pilot scale. The manufacturing route therefore specifies reconstitution in Water for Injection at 60 °C, adjustment to pH 6.8–7.2 with tromethamine, and addition of sodium chloride to 0.9% w/v for isotonicity. The bulk solution is clarified through a 0.45 µm depth filter, then sterilized through a 0.22 µm membrane. Terminal steam sterilization at 121 °C for 15 min is not automatically applied because flavonoid marker recovery can vary with heating time and dissolved oxygen exposure; published data for this specific extract configuration is limited, so filter compatibility and heat-recovery studies must be generated for each lot. Phosphate buffers are avoided because polyvalent phosphate species can precipitate with calcium or ferric ions co-extracted in the botanical powder. Calcium gluconate and ferric dextran admixtures are incompatible in the final injectable solution due to dark tannin-metal complex formation. The finished injectable is filled into 20 mL or 50 mL Type I glass vials with nitrogen headspace, protected from light, and released by sterility, endotoxin, and particulate matter tests. Filter membrane area is determined by bench-scale Vmax tests rather than nominal pore-size rating alone because the extract contains a small fraction of deformable submicron particulate that compresses under process pressure. Post-filling integrity testing by bubble point or forward flow is performed as part of sterility assurance under USP <71>.

For high-volume poultry and swine capsule programs, the vacuum-dried or spray-dried API cannot be filled accurately on dosator machines without densification because its bulk density is low, dusting is severe, and hopper flow is irregular at fill speeds above 60,000 capsules/hour. The powder is first passed through a roller compactor with roll pressure 4–6 MPa, milled through a 0.8 mm screen, and blended with microcrystalline cellulose 102, croscarmellose sodium 2% w/w, and colloidal silicon dioxide 0.5% w/w. The dry granulate is filled into size 0 or size 1 hard gelatin capsules at a target total mass of 350 mg and an API load of 150 mg per capsule. In-process moisture is held below 5.0% w/w because higher residual moisture causes gelatin cross-linking, delayed disintegration, and capsule shell softening during storage above 30 °C. Dissolution testing follows USP <711> apparatus 2 in 0.1 N HCl with a provisional acceptance of not less than 70% baicalin release at 45 min. Microbiological release limits for this nonsterile oral dosage form are total aerobic microbial count not more than 10^4 CFU/g by USP <61>, absence of Salmonella by USP <62>, and absence of Escherichia coli by USP <62>. Heavy metals are controlled by USP <232>/<233>, and residual solvents by USP <467> or VICH GL18 for veterinary submissions. The finished capsules are packed in high-density polyethylene bottles with a desiccant canister because the botanical extract re-equilibrates with ambient moisture within 12 h when exposed at 60% relative humidity at production scale.

Fluidized-bed granulation endpoints for reconstitutable oral granules

Aqueous dispersible granules for oral administration are produced when the API is agglomerated with lactose monohydrate and pregelatinized starch in a top-spray fluidized bed at inlet air 65–70 °C and product bed temperature 35–40 °C. The binder is a 5% w/w maltodextrin solution sprayed at 8–10 g/min per kg of substrate; after spray completion the bed is dried to a loss on drying of 2.0–3.5% and sieved to retain 0.25–0.80 mm granules. Oversized granules are rejected because they settle too quickly in drinking-water lines, and fines below 0.25 mm create dust and poor wetting. The granulate is filled into 100 g aluminium/PVC sachets under 25% relative humidity. At the farm, the granulate is dispersed at 1 g/L in chlorinated drinking water; where total hardness exceeds 180 mg/L as calcium carbonate, a stock solution prepared at 20 g/L is preferred to avoid undissolved residues in nipple drinkers. The finished sachet product is controlled for moisture by USP <731>, for aerobic microbial count by USP <61>, and for aflatoxin status by a validated LC-MS/MS method aligned with ISO 16050 or equivalent feed-safety guidance. Because the flavonoid fraction undergoes oxidative browning in aqueous dispersion, the diluted granulate is not stored overnight in header tanks; field stock tanks are flushed at the end of each administration cycle to avoid biofilm adhesion in metering pumps.

When the API is dispersed in dry feed premix for grower-finisher rations

When Dahuang Huangqin Powder Veterinary Grade API is incorporated into medicated feed, the primary process risk is not dissolution but mixing uniformity and segregation after discharge. The API is pre-blended with ground rice hulls or calcium carbonate in a 1:9 ratio in a 200 L ribbon blender for 10 min, then diluted with additional carrier to a final in-feed concentration of 0.5–2.0 kg per tonne of finished feed. Ten-point sampling and baicalin assay are performed according to the sampling plan of ISO 6497, with acceptance of coefficient of variation ≤ 5.0%. Batch-to-batch variability in the API assay and loss on drying must be compensated by adjusting the weigh-out on a dry-weight basis. The premix is packaged in paper-PE bags with a moisture vapour transmission rate below 5 g/m²/day. Pellet conditioning is restricted to 75–80 °C for no more than 30 s because anthraquinone glycosides degrade under prolonged moist heat; if higher temperature pelleting is unavoidable, post-pelleting liquid spray application is used. Premix with high reducing sugars or unfermented soybean meal should be avoided due to browning and potential degradation of flavonoid constituents during storage. Production-scale cleanout between batches uses a 1:1 carrier flush of 50 kg ground rice hulls, followed by visual inspection of dead zones in the ribbon mixer, to reduce cross-batch carryover below 0.1% of the label claim.

Drinking-water delivery of Dahuang Huangqin Powder Veterinary Grade API is governed by dissolution rate, water hardness, and biofilm interaction in nipple drinkers rather than by the compressibility or segregation parameters that dominate solid dosage processing. Unmodified extract dispersed into cold hard water at 15 °C and calcium carbonate content above 180 mg/L forms a sticky sediment in header lines and reduces flow through metering pumps. A co-processed water-soluble powder is therefore manufactured by blending the API with sodium bicarbonate and anhydrous lactose as carriers, plus 2% w/w colloidal silicon dioxide, and the mixture is filled into 100 g water-soluble sachets. Field dilution is 100 g per 100 L of drinking water under continuous agitation, but the resulting solution is used within 6 h unless a preservative system is included because the decoction solids support rapid microbial growth and flavonoid oxidation at ambient temperature. Stock tanks, proportioner pumps, and nipple lines must be flushed daily; chlorine residuals above 2 mg/L can reduce marker compound recovery by oxidative degradation and should be neutralized with sodium thiosulfate at 5–10 mg/L before addition. Release testing follows USP <61> for total aerobic count, USP <62> for Escherichia coli and Salmonella, and residual solvent testing by USP <467>, with a loss on drying limit of 5.0% w/w. The terminal finished product is a foil over-wrap sachet for short-term oral treatment in poultry and swine; if the product is delivered through a proportioner, the stock concentration is increased to 50 g/L and the pump is calibrated daily because particulate residue can shift the metering diaphragm over repeated cycles.

Aqueous stability constraints limit oral drench compounding to 24-hour use

Oral drench solutions for calves and piglets are compounded at 10 g/L in deionized water, adjusted to pH 6.5–7.0 with trisodium citrate dihydrate, and filled into 500 mL amber HDPE bottles. The solution remains visibly clear for 24 h at 4–8 °C; above 30 °C sedimentation appears and microbial proliferation initiates unless potassium sorbate 0.1% w/w is added. Heat sterilization is not used because terminal autoclaving reduces baicalin recovery and darkens the product. Strainer sieves of 0.150 mm are placed in the filling line to remove botanical microparticles that pass through the clarification step. Finished solution is dispensed with a graduated drenching gun; dose volumes are calculated from animal body weight and the baicalin assay of the API lot, with the stock solution retained for no more than 1 working day. The product is controlled as a nonsterile aqueous preparation under USP <61>, with pH by USP <791>, preservative assay by a stability-indicating HPLC method, and heavy metals by USP <232>/<233>. Avoid concurrent administration with mineral antacids containing aluminum or magnesium because tannate and flavonoid-metal complexes reduce bioavailability and create pipe-clogging particulate matter in drinking equipment.